Happy to see our study on the dynamics of HIV-1 neutralisation finally published Nature Medicine! 🔥🔥🔥Thanks to the whole team, including colleagues from all over the world and of course to all the people living with #HIV who participated! nature.com/articles/s4159…

Among comatose patients w/ suspected acute poisoning, a conservative strategy of withholding intubation was associated w/ a greater clinical benefit for the composite end point of in-hospital death, length of ICU stay & length of hospital stay. ja.ma/3GmzsDG #CCCF2023

Presented now at #ASH23 by Othman Al-Sawaf: In a phase 2 trial, anti-PD-1 inibitor tislelizumab + next gen BTK inhibitor zanubrutinib had an overall response rate of 58.3% in patients with Richter's transformation Universität zu Köln Uniklinik Köln #leusm #lymsm #CLL doi.org/10.1038/s41591…

Warnstreik am 30. Januar 2024: Die Ärztegewerkschaft Marburger Bund hat einen ganztägigen #Warnstreik angekündigt. Auch an der #Uniklinik #Köln sind deutliche Einschränkungen in der Patientenversorgung zu erwarten. Weitere Informationen: uk-koeln.de/uniklinik-koel…

⚠️#RT is a major challenge in #CLL. At #ESHCLL2024 a truely translational session led by Elisa ten Hacken, Bill Wierda, MD, PhD, E. Campo, and Toby Eyre explored tumor models, genomic landscape and therapies in RT, offering a comprehensive overview and sparking discussion. #ESHCONFERENCES

The 1. day of #ESHCLL2024 ends with a captivating translational session on #CLL #TME. Michael Hallek, @Seiffert_lab, E. Elderling, Hien Nguyen, and A. Wiestner delve into the impact of immunotherapy, metabolism, and kinase-targeting. Interesting times ahead testing those clinically!

Excited to announce I received an Emmy Noether fellowship from DFG public | @[email protected] to set up a research lab 🔬 on the evolution&plasticity of #CLL & other #cancers Uniklinik Köln CECAD Cologne Cologne🇪🇺🇩🇪! Fully funded PhD student & postdoc positions available-get in touch to connect via email&DM!

The 13th International Symposium on Hodgkin Lymphoma (#ISHL13) will be held October 26-28, 2024 in Cologne. Browse the detailed program 👀🗓️, register at early bird rate🐦⏰ and submit your abstract 📜📨now, to share & discuss your research at #ISHL13: hodgkinsymposium.org

New Research: 4-year follow-up of GAIA/CLL13: First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic #leukaemia thelancet.com/journals/lanon… #CLL #leusm

One of the most pressing questions in the era of caplacizumab is if iTTP can be managed without plasma exchange! Check out our paper addressing this question: Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange ashpublications.org/blood/article-…

GHSG HD21 trial results The Lancet: Unprecedented outcomes in advanced-stage cHL. PET-guided BrECADD superior to eBEACOPP: Better tolerability, higher dose density and 4y PFS 94.3%. Congrats to everyone involved - truly great international academic effort t.ly/TrZHU

Check out our latest paper in Journal of Clinical Oncology on surrogacy of endpoints in 1L #CLL trials! Led by Florian Simon, we systematically studied the association of PFS and MRD with OS. Some findings in a brief 🧵 👇 ascopubs.org/doi/10.1200/JC…

Please appreciate this tweetorial by Othman Al-Sawaf on our paper on surrogate endpoints in 1L CLL just published in Journal of Clinical Oncology ! What a ride but I could not be more grateful to Othman for approaching me with this idea and being the very definition of a mentor throughout! 🙏

Great to finally see this important study utilizing ctDNA for biologic classification and risk stratification of Hodgkin lymphoma with contemporary treatment led by @miheger Uniklinik Köln published Journal of Clinical Oncology. Congrats to everyone involved! ascopubs.org/doi/10.1200/JC…

End Point Surrogacy in First-Line CLL: Given the clear PFS benefit in patients who achieve undetectable MRD after therapy, novel strategies incorporating MRD as an endpoint are ready for evaluation as a precision approach to CLL therapy. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

One week from now, the 13th International Symposium on Hodgkin Lymphoma #ISHL13 will kick-off in Stadt Köln with >600 international attendees 🧑‍⚕️👩‍🔬🌍 Browse the >100 scientific abstracts which are available online now and will be published HemaSphere Journal (IF = 14.6) 📒📊👀hodgkinsymposium.org/abstracts-publ…

Our latest paper on Ven-Obi in 1L #CLL is now online & in the current issue of @BloodJournal! ashpublications.org/blood/article/… Main results in a quick 🧵 👇

Delighted to share our manuscript from The Lancet Haematology Commission on Adverse Events We focus on optimising assessment of toxicity and tolerability in patients receiving novel therapies Led by the fab Paul Bröckelmann thelancet.com/journals/lanha… #lymsm Florian Simon Gloria Iacoboni

Great to join Paul Bröckelmann presenting data from our recent The Lancet Haematology commission on adverse events, starting with the paper by Ajay Major, MD, MBA Amylou Dueck, PhD on advancing AE measurement #EHA2025 Gita Thanarajasingam

Listening for the journey home - new The Lancet Haematology podcast featuring a discussion of our commission on adverse events in haematology open.spotify.com/episode/5kT1Ya… #EHA2025